\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
Roblox’s vision of bringing others together through shared experiences, coupled with Akili’s commitment to a new era of cognitive medicine, make corporations ideal partners in delivering a reimagined patient experience.
BOSTON, May 26, 2022–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapy company, has noted that its founding entity, Akili Interactive Labs, Inc. (“Akili”), a leading virtual medicine company pioneering the progression of cognitive remedies through innovative technologies, and Roblox (NYSE: RBLX), a global platform that brings millions of others together through shared experiences, announced a collaboration that connects patients’ medical remedies to their favorite virtual worlds.
Through this partnership, Akili and Roblox are introducing new tactics to integrate medicine into patients’ lives. As a first step, corporations will identify an exclusive Roblox rewards exchange connected to Akili’s EndeavorRx®, the first and only prescription video game remedy for youth with ADHD, legal through the U. S. Food and Drug Administration. USA (see full indication below). Companies are exploring new approaches and more opportunities to interact with Akili patients through Roblox integrations.
Akili’s full announcement is as follows:
Akili Integrates One-of-a-Kind Prescription Video Game Treatment with Virtual World Partnership with Roblox
Roblox’s vision of bringing others together through shared experiences, coupled with Akili’s commitment to a new era of cognitive medicine, make corporations ideal partners in delivering a reimagined patient experience.
BOSTON, Mass. et SANTA MONICA, Calif. –May 26, 2022 – Akili Interactive (“Akili”), a leading virtual medicine company pioneering the progression of cognitive remedies through innovative technologies, and Roblox (NYSE: RBLX), a global platform bringing millions of others together through shared experiences, announced a collaboration that connects patients’ medical remedies to their favorite virtual worlds.
“Roblox brings tens of millions of other people together every day to connect, create and express themselves, and we’re proud to work with Akili to tap into that hobby and laugh as part of their best-in-class virtual processing. “”said Craig Donato, Roblox’s chief commercial officer. ” Akili has captured our attention with its prescription remedy for children with ADHD provided through an action play experience and stores our vision and enthusiasm for what is imaginable through interactive virtual games. We are proud to help them as they lead the effort to achieve new perspectives in the medical field. “
Through this partnership, Akili and Roblox are introducing new tactics to integrate medicine into patients’ lives. As a first step, corporations will identify a Roblox-exclusive rewards exchange similar to Akili’s EndeavorRx® remedy (see full indication below). Companies are exploring new approaches and more opportunities to interact with Akili patients through Roblox integrations.
“We are committed to improving cognitive fitness around the world through remedies that interact and surprise patients,” said Eddie Martucci, CEO and co-founder of Akili Interactive. “Our FDA-approved video game remedy proves that the medicine can be enjoyable, and this is just the beginning. Akili’s long-term vision is to integrate virtual medicine into patients’ daily lives in a way never before seen or experienced. Roblox has replaced the way millions of other people learn, paint, connect and play, and we are excited to work in combination to push the barriers of our industries even further and continue to redefine the medical experience. “
Akili and Roblox are herbal partners. Akili challenged classical perceptions of medicine and created EndeavorRx®, the first and only prescription video game remedy for young people with ADHD, licensed by the U. S. Food and Drug Administration. U. S. (FDA). With more than 55 million people worldwide coming in combination every day at Roblox, Roblox powers a platform for shared immersive three-dimensional experiences. Together, they have the ability to reinvent the patient experience.
Indication and review of EndeavorRx®
EndeavorRx® is indicated for improving attention as measured by automated tests in youth 8 to 12 years of age with ADHD of the predominantly inattentive or combined type, who have a demonstrated challenge with attention. Patients interacting with EndeavorRx® demonstrate innovations in a Numerically Assessed Attention Variables (TOVA®) test of sustained and selective attention and may show no benefit in typical behavioral symptoms, such as hypoconsistency with activity. EndeavorRx® deserves to be considered as part of a healing program that would possibly come with physician-directed therapy, medications, and/or educational programs, which better address the symptoms of the disorder. EndeavorRx® is available by prescription only. It is not intended to be used as a stand-alone remedy and does not update a child’s medicine. Adverse events related to EndeavorRx® in clinical trials include frustration (6. 1%), headache (1. 3%), dizziness (0. 6%), emotional reaction (0. 4%), nausea (0 . 4%) and aggressiveness (0. 2%). ). No serious adverse events have been associated with its use. It is recommended that EndeavorRx® be used for approximately 25 minutes a day, five days a week, for at least four consecutive weeks initially, or as advised by your child’s physical care provider. To learn more about EndeavorRx®, visit EndeavorRx. com.
About Roblox
Roblox is reinventing the way other people combine to bond, create and express themselves through immersive and interactive shared experiences. Every day, millions of other people around the world play, learn, talk and expand their friendships by exploring millions of users generated virtual experiences, all designed through creators on the platform. Our project is to unite billions of users with courtesy and optimism to a secure and varied network, which inspires and fosters creativity and positive relationships among other people around the world. For more information, scale in corp. roblox. com.
About Akili
Akili is a pioneer in the progression of cognitive remedies through revolutionary technologies. Our technique of leveraging technologies designed to directly target the brain establishes a new category of medicine: medicine validated through clinical trials as a drug or medical device, but experienced as entertainment. Akili’s platform is powered by proprietary healing engines designed to target cognitive decline at its source in the brain, informed through decades of studies, and validated through rigorous clinical programs. Driven by Akili’s confidence that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, visit www. akiliinteractive. com.
Forward-Looking Statements
This communication may involve certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are sometimes known by the words “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “long-term”, “opportunity”, ” to plan”. , “possibly”, “should”, “will”, “will”, “continue”, “most likely will” and similar expressions and come with statements regarding Akili’s expectations for EndeavorRx® and digital medicine, your association with Roblox and the expected benefits of it. Forward-looking statements are predictions, projections and other statements about long-term events that are based on existing expectations and assumptions and, accordingly, are subject to threats and uncertainties. Many items may also cause actual long-term events to differ materially from the forward-looking statements involved in this communication, including, but not limited to, (i) Akili’s ability to effectively market EndeavorRx® and continue to advance its clinical progression channel, (ii) Akili’s ability to maintain relationships with its consumers and suppliers and retain its executives and key employees, (iii) the evolution of the market positions in which Akili competes, (iv) the ability of Akili to protect its intellectual assets and comply with regulatory requirements, (v) the effect of the COVID-19 pandemic on Akili’s business, (vi) Akili’s expectations regarding its market position opportunities; and (vii) the threat of a recession and the changing regulatory landscape in the highly competitive industry in which Akili operates. The above list of points is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on any forward-looking statements, and Akili assumes no legal responsibility and does not intend to update or revise any such forward-looking statements, whether as a result of new information, long-term events or another way. Akili does not guarantee that it will meet your expectations.
About PureTech Health
PureTech is a clinical-stage biohealing company committed to the discovery, progression, and commercialization of highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, incurable cancers, lymphatic and gastrointestinal diseases, and neurological and neuropsychological disorders, among others. The company has built a broad and deep portfolio through the expertise of its experienced study and progression team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is progressing both internally and through PureTech’s founded entities, includes 25 curative products and curative applicants, two of which have obtained US FDA clearance and marketing authorization. the European market, as of the date of the last semi-annual report presented through PureTech. and the corresponding Form 6-K. All of the underlying systems and platforms that resulted in this line of healing seekers were first known or discovered and then complexed through the PureTech team through key validation issues based on the company’s proprietary wisdom about the biology of the brain, immune, and gut, or BIG, systems and the interface between those systems, called the BIG Axis.
For more information, visit www. puretechhealth. com or connect with us on Twitter @puretechh.
Cautionary Note On Forward-Looking Statements
This press release comprises emails that are or may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All messages in this press release that do not relate to past events deserve to be considered forward-looking – Looking s. Array including but not limited to s related to Akili’s expectations related to EndeavorRx® and virtual medicine, its association with Roblox and the expected benefits thereof, the competitive environment in which Akili operates and prospects, Akili and Pure Tech methods and progression plans. Forecasts are based on existing expectations and are subject to known and unknown risks, uncertainties, and other vital points that may also cause actual results, functionality, and achievements to differ. materially from existing expectations, including, but not limited to, those risks, uncertainties and other items v those described under “Risk Factors” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2021 filed with the SEC and in our other regulatory documents. These forecasts are based on assumptions about the Company’s supply and long-term business methods and the environment in which it will operate in the long term. Each prospect speaks only as of the date of this press release. Except as required by law and regulatory requirements, we disclaim any legal responsibility to update or revise such prospective emails, whether as a result of new information, long-term events, or otherwise.
See the businesswire. com edition: https://www. businesswire. com/news/home/20220525005702/en/
Contacts
PureTech Public Relationspublicrelations@puretechhealth. com Investor RelationsIR@puretechhealth. com
European media Ben Atwell, Rob Winder (0) 20 3727 1000ben. atwell@FTIconsulting. com
U. S. Media Nichole Sarkis 1,774,278 8273nichole@tenbridgecommunications. com